These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22543830)

  • 1. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
    Inokura K; Onishi Y; Shimosegawa K; Okitsu Y; Katsuoka Y; Fujiwara T; Fukuhara N; Ishizawa K; Harigae H
    Ann Hematol; 2012 Nov; 91(11):1825-6. PubMed ID: 22543830
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
    Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
    Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
    [No Abstract]   [Full Text] [Related]  

  • 5. The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for chronic myelogenous leukemia.
    Wakim JJ; Tirado CA; Dowell J; Chen W
    Cancer Genet; 2012 Mar; 205(3):124-7. PubMed ID: 22469511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.
    Assouline S; Laneuville P; Gambacorti-Passerini C
    N Engl J Med; 2006 Jun; 354(24):2623-4. PubMed ID: 16775249
    [No Abstract]   [Full Text] [Related]  

  • 7. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of imatinib in the treatment of acute lymphoid leukemias].
    Poros A; Lovas N
    Orv Hetil; 2005 May; 146(18 Suppl 1):905-10. PubMed ID: 15921303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic efficacy of imatinib mesylate (glivec) in chronic phase of myeloid leukemia].
    Turkina AG; Khoroshko ND; Druzhkova GA; Zingerman BV; Zakharova ES; Chelysheva EIu; Vinogradova OIu; Domracheva EV; Zakharova AV; Kovaleva LG
    Ter Arkh; 2003; 75(8):62-7. PubMed ID: 14520855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral neuropathy as an adverse effect of imatinib therapy.
    Chakupurakal G; Etti RJ; Murray JA
    J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
    Jabbour EJ; Kantarjian H; Eliasson L; Cornelison AM; Marin D
    Am J Hematol; 2012 Jul; 87(7):687-91. PubMed ID: 22473898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
    Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
    J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia.
    Ross DM; Jackson SR; Browett PJ
    Leuk Lymphoma; 2007 Jun; 48(6):1231-3. PubMed ID: 17577792
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chronic myeloid leukemia and imatinib mesylate therapy].
    Chrobák L
    Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
    [No Abstract]   [Full Text] [Related]  

  • 18. Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country.
    Aziz Z; Iqbal J; Bano K; Faisal M; Akram M
    Jpn J Clin Oncol; 2010 Jun; 40(6):549-55. PubMed ID: 20189974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
    Eskazan AE; Ayer M; Kantarcioglu B; Arica D; Demirel N; Aydin D; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Br J Haematol; 2014 Oct; 167(1):139-41. PubMed ID: 24815307
    [No Abstract]   [Full Text] [Related]  

  • 20. Loss of skin pigment caused by imatinib therapy.
    McPartlin S; Leach M
    Br J Haematol; 2005 May; 129(4):448. PubMed ID: 15877727
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.